

Biocon Biologics Limited

CIN: U24119KA2016PLC093936

Biocon House, Tower-3,
Semicon Park Electronic City, Phase - II,
Hosur Road, Bengaluru, Karnataka 560100 IN**T** +91 080-6775 6775, **F** +91 080-6775 1030**E** contact@bioconbiologics.comwww.bioconbiologics.com

December 1, 2024

Singapore Exchange Securities Trading Limited

4 Shenton Way # 02-01

SGX Centre 2 Singapore 068807

Dear Sir/Madam,

Subject: Company Statement

Please find enclosed the company statement titled “**U.S.FDA Approves Biocon Biologics’ YESINTEK™, Bmab 1200 biosimilar to J&J’s Stelara® (Ustekinumab).**”

Kindly take the same on record and acknowledge.

Thanking you

Your faithfully

For Biocon Biologics Limited

Akhilesh
Nand

Digitally signed
by Akhilesh Nand
Date: 2024.12.01
13:20:09 +05'30'

Akhilesh Nand

Company Secretary

Membership No. ACS 13669

Encl: as above

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

**U.S.FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200
biosimilar to J&J's Stelara® (Ustekinumab)**

Bengaluru, Karnataka, India, December 01, 2024

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the **U.S. Food and Drug Administration (FDA) has approved YESINTEK™ (Ustekinumab-kfce)**, a biosimilar to the reference product, Stelara® (Ustekinumab).

YESINTEK™, a monoclonal antibody, is approved for the treatment of Crohn's disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis.

Biocon Biologics Ltd had previously notified the Stock Exchange on Feb 29, 2024, that the Company had entered into a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) **to commercialize YESINTEK™ in the United States of America no later than on February 22, 2025, upon approval from the U.S. FDA.**

– Company Spokesperson

For more information: seema.ahuja@biocon.com